Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer (Q39177574)

9 September 2017

Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer (English)

1 reference

9 September 2017

0 references

1 reference

1

0 references

Jürgen Debus

9

object named as

Jürgen Debus

1 reference

9 September 2017

8

Markus W Büchler

1 reference

9 September 2017

3

Kerstin A Kessel

1 reference

9 September 2017

Daniel Habermehl

2

1 reference

9 September 2017

Frank Bergmann

4

1 reference

9 September 2017

Jens Werner

5

1 reference

9 September 2017

Patrick Naumann

6

1 reference

9 September 2017

Dirk Jäger

7

1 reference

9 September 2017

language of work or name

1 reference

11 June 2014

1 reference

Annals of Surgical Oncology

9 September 2017

1 reference

9 September 2017

21

1 reference

9 September 2017

8

1 reference

9 September 2017

2801-2807

1 reference

https://scigraph.springernature.com/pub.10.1245/s10434-014-3607-8

9 September 2017

0 references

cites work

Specific Antigen in Serum of Patients with Colon Carcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Colorectal carcinoma antigens detected by hybridoma antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection : Analysis of treatment efficacy and failure in patients receiving postoperative or primary chemoradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Nutritional surveillance and weight loss in head and neck cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

The effect of preoperative weight loss and body mass index on postoperative outcome in patients with esophagogastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: a large single-institution study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Impact of obesity on perioperative morbidity and mortality after pancreaticoduodenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Cachexia worsens prognosis in patients with resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

The role of the FOLFIRINOX regimen for advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Nutritional counselling and oral nutritional supplements in head and neck cancer patients undergoing chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

Most Pancreatic Cancer Resections are R1 Resections

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3607-8

10.1245/S10434-014-3607-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

9 September 2017

0 references

1 reference